Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375
This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.
To this end data was pooled from DISCOVER-1 and DISCOVER-2 Phase 3 studies to assess guselkumab efficacy through 1 year utilizing various composite indices of PsA disease activity.
Researchers therefore concluded that guselkumab can provide effective treatment of the diverse manifestations of PsA, providing clinicians with an effective treatment tool in their practice.